These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38813759)

  • 1. Subanesthetic S-ketamine does not acutely alter striatal dopamine transporter binding in healthy Sprague Dawley female rats.
    Bærentzen SL; Thomsen JB; Thomsen MB; Jakobsen S; Simonsen MT; Wegener G; Brooks DJ; Landau AM
    Synapse; 2024 Jul; 78(4):e22294. PubMed ID: 38813759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
    Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
    Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
    Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
    J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
    Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
    Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
    J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand
    Lizana H; Johansson L; Axelsson J; Larsson A; Ögren M; Linder J; Halldin C; Varrone A; Mo SJ
    J Nucl Med; 2018 Aug; 59(8):1275-1280. PubMed ID: 29348315
    [No Abstract]   [Full Text] [Related]  

  • 8. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter.
    Emond P; Guilloteau D; Chalon S
    CNS Neurosci Ther; 2008; 14(1):47-64. PubMed ID: 18482099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter.
    Schou M; Steiger C; Varrone A; Guilloteau D; Halldin C
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4843-5. PubMed ID: 19577467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.
    Chalon S; Hall H; Saba W; Garreau L; Dollé F; Halldin C; Emond P; Bottlaender M; Deloye JB; Helfenbein J; Madelmont JC; Bodard S; Mincheva Z; Besnard JC; Guilloteau D
    J Pharmacol Exp Ther; 2006 Apr; 317(1):147-52. PubMed ID: 16339913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electroconvulsive therapy decreases striatal dopamine transporter binding in patients with depression: A positron emission tomography study with [
    Masuoka T; Tateno A; Sakayori T; Tiger M; Kim W; Moriya H; Ueda S; Arakawa R; Okubo Y
    Psychiatry Res Neuroimaging; 2020 Jul; 301():111086. PubMed ID: 32464340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand.
    Varrone A; Steiger C; Schou M; Takano A; Finnema SJ; Guilloteau D; Gulyás B; Halldin C
    Synapse; 2009 Oct; 63(10):871-80. PubMed ID: 19562698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells.
    Page G; Chalon S; Emond P; Maloteaux JM; Hermans E
    Neurochem Int; 2002 Feb; 40(2):105-13. PubMed ID: 11738476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of the striatal dopamine transporter density and heterogeneity in type 1 alcoholics using human whole hemisphere autoradiography.
    Tupala E; Kuikka JT; Hall H; Bergström K; Särkioja T; Räsänen P; Mantere T; Hiltunen J; Vepsäläinen J; Tiihonen J
    Neuroimage; 2001 Jul; 14(1 Pt 1):87-94. PubMed ID: 11525341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter.
    Chalon S; Garreau L; Emond P; Zimmer L; Vilar MP; Besnard JC; Guilloteau D
    J Pharmacol Exp Ther; 1999 Nov; 291(2):648-54. PubMed ID: 10525084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal DAT changes measured with [
    Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
    Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine alters the availability of striatal dopamine transporter as measured by [(11)C]beta-CFT and [(11)C]beta-CIT-FE in the monkey brain.
    Tsukada H; Nishiyama S; Kakiuchi T; Ohba H; Sato K; Harada N
    Synapse; 2001 Dec; 42(4):273-80. PubMed ID: 11746726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of [(18)F]beta-CFT-FE (2beta-carbomethoxy-3beta-(4-fluorophenyl)-8-(2-[(18)F]fluoroethyl)nortropane) as a dopamine transporter ligand: A PET study in the conscious monkey brain.
    Harada N; Ohba H; Fukumoto D; Kakiuchi T; Tsukada H
    Synapse; 2004 Oct; 54(1):37-45. PubMed ID: 15300883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine decreased striatal [(11)C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis.
    Tsukada H; Harada N; Nishiyama S; Ohba H; Sato K; Fukumoto D; Kakiuchi T
    Synapse; 2000 Aug; 37(2):95-103. PubMed ID: 10881030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.